Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
(New page: {| class="wikitable" border="0px" width="100%" style="text-align:center" |- ! colspan="5" align="center"| DPP4 Inhibitor Pharmacokinetics |- ! Parameter ! Vildagliptin<br/>(Galvus...) |
|||
(9 intermediate revisions not shown.) | |||
Line 9: | Line 9: | ||
|- | |- | ||
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) | ||
- | ! | + | ! 1.75 |
- | ! | + | ! 1-4 |
- | ! | + | ! 2 |
|- | |- | ||
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) | ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) | ||
- | ! | + | ! 290 |
- | ! | + | ! 330 |
- | ! | + | ! 34 |
|- | |- | ||
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) | ||
- | ! | + | ! 85 |
- | ! | + | ! 87 |
- | ! | + | ! 67 |
|- | |- | ||
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) | ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) | ||
- | ! | + | ! 9 |
- | ! | + | ! 38 |
- | ! | + | ! 0 |
|- | |- | ||
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) | ||
- | ! | + | ! 2-3 |
- | ! | + | ! 12.4 |
- | ! | + | ! 2.5 |
|- | |- | ||
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
- | ! | + | ! 1610 |
- | ! | + | ! 3470 |
- | ! | + | ! 101 |
|- | |- | ||
! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
- | ! | + | ! 3 |
- | ! | + | ! 18 |
- | ! | + | ! 50 |
|- | |- | ||
- | ! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) | + | ! [[Pharmacokinetics#Clearance_.28Cl.29|Renal Clearance]] (L/h) |
- | ! | + | ! 13.0 |
- | ! [[ | + | ! 21.0 |
- | ! | + | ! 13.8 |
+ | |- | ||
+ | ! [[Pharmacokinetics#Volume_of_Distribution_.28Vd.29|Volume Distribution]] (L) | ||
+ | ! 71 | ||
+ | ! 198 | ||
+ | ! 151 | ||
|- | |- | ||
! Dosage (mg) | ! Dosage (mg) | ||
- | ! | + | ! 100 |
- | ! | + | ! 100 |
- | ! | + | ! 5 |
|- | |- | ||
! Metabolism | ! Metabolism | ||
- | ! | + | ! Hydrolysis |
- | ! | + | ! Hepatic (CYP3A4 & CYP2C8) |
- | ! | + | ! Hepatic (CYP3A4) |
|} | |} | ||
- | For Pharmacokinetic Data References, see: [[Treatments: | + | For Pharmacokinetic Data References, see: [[Treatments:Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics|References]] |
Current revision
DPP4 Inhibitor Pharmacokinetics | ||||
---|---|---|---|---|
Parameter | Vildagliptin (Galvus) | Sitagliptin (Januvia) | Saxagliptin (Onglyza) | |
Tmax (hr) | 1.75 | 1-4 | 2 | |
Cmax (ng/ml) | 290 | 330 | 34 | |
Bioavailability (%) | 85 | 87 | 67 | |
Protein Binding (%) | 9 | 38 | 0 | |
T1/2 (hr) | 2-3 | 12.4 | 2.5 | |
AUC (ng/ml/hr) | 1610 | 3470 | 101 | |
IC50 (nM) | 3 | 18 | 50 | |
Renal Clearance (L/h) | 13.0 | 21.0 | 13.8 | |
Volume Distribution (L) | 71 | 198 | 151 | |
Dosage (mg) | 100 | 100 | 5 | |
Metabolism | Hydrolysis | Hepatic (CYP3A4 & CYP2C8) | Hepatic (CYP3A4) |
For Pharmacokinetic Data References, see: References